Brief: HBM Holdings Says Co And AstraZeneca Entered Global Out-License Agreement
07/04/2022 24:35
April 7 (Reuters) - HBM Holdings Ltd 2142.HK :
* CO AND ASTRAZENECA ENTERED INTO A GLOBAL OUT-LICENSE
AGREEMENT
* AGREEMENT TO DEVELOP & COMMERCIALIZE HBM7022, A NOVEL
BISPECIFIC
ANTIBODY GENERATED FROM HCAB BASED IMMUNE CELL ENGAGERS PLATFORM
* PURSUANT TO LICENSE DEAL, CO SHALL RECEIVE UPFRONT PAYMENT
OF
US$25 MILLION WITH POTENTIAL FOR ADDITIONAL PAYMENTS UP TO
US$325 MILLION
Further company coverage: 2142.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HBM Holdings
See all newsBrief: HBM Holdings Says NMPA Approves Batoclimab Injection For Generalized Myasthenia Gravis
HBM climbs on development of AI biology foundation model
Brief: HBM Holdings' Unit Develops World's First Language Model For Fully Human Heavy-Chain-Only Antibodies
Brief: Hbm Holdings Says Solstice Oncology Launches Series A Financing Round
HK-listed HBM climbs on initiating next phase of asthma drug study